BridgeBio Pharma (BBIO) Operating Lease Liability - Undiscounted Excess Amount — Quarterly & Annual

Screener

Operating Lease Liability - Undiscounted Excess Amount at other companies

Zevra Therapeutics, Inc.ZVRA

$247K-26.9%

Mirum Pharmaceuticals, Inc.MIRM

$2.49M+52.4%

Other financials

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.

The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.

Filed: Aug 10, 2026, 4:31 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001743881-26-000027

Line item	Amount	Amount
2031	3,031
Thereafter	4,675
Total future minimum lease payments	22,961
Imputed interest	(4,673)
Total	$	$18,288
Reported as of June 30, 2026
Operating lease liabilities, current portion	$	$3,315
Operating lease liabilities, net of current portion	14,973

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's operating lease liability - undiscounted excess amount?: BridgeBio Pharma (BBIO) reported operating lease liability - undiscounted excess amount of $4.67M in Q2 2026.
What does operating lease liability - undiscounted excess amount mean?: This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.

Ask your AI about BridgeBio Pharma's operating lease liability - undiscounted excess amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk